SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
Molecular testing practice patterns for lung cancer based on gender: Insights into disparities and opportunities for precision medicine. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...
Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno Broadly, PFS2 has been used in oncology trials to evaluate ...
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...
A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern. A population-based study from Sweden upends conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results